News about Market

Dadachanji Group Launches KAISHA Pharma

Dadachanji Group launches Kaisha Pharma with a complete tubular glass portfolio and advanced Ready-To-Use (RTU) platforms for vials, syringes and cartridges.

Market | 04/09/2026 | By News Bureau |  140

Cohance Lifesciences Advances its ADC Strategy Investment of USD 18 million in NJ Bio and Aruka Bio

Cohance Lifesciences invests USD 18 million in NJ Bio and Aruka Bio to strengthen its ADC strategy, customer services and proprietary pipeline development.

Market | 04/09/2026 | By News Bureau

Vertex Completes Acquisition of Crinetics Pharmaceuticals

Vertex completes its acquisition of Crinetics Pharmaceuticals on September 1, 2026, expanding its portfolio and executive leadership team.

Market | 04/09/2026 | By News Bureau |  122

Ono Pharma Enters into Drug Discovery Partnership with Aitia in Neurological Diseases

Ono Pharma partners with Aitia to use causal Artificial Intelligence (AI) and Gemini Digital Twins for novel drug target discovery in neurological diseases.

Market | 03/09/2026 | By News Bureau

Cipla Partners with CTTQ to Develop and Commercialise HER2-Targeted ADC in Emerging Markets

Cipla and CTTQ partner to expand access to TQB2102, an investigational HER2 bispecific ADC being evaluated across HER2-expressing cancers.

Market | 01/09/2026 | By News Bureau |  114

Eli Lilly to Acquire Merida Biosciences in Deal Valued at Up to USD 2.875 Billion

Eli Lilly will acquire Merida Biosciences for up to $2.875 billion to advance precision therapies targeting disease-causing autoantibodies.

Market | 01/09/2026 | By News Bureau |  123

RedHill Biopharma Divests Talicia Business to Apotex for USD 18 Million Upfront

RedHill Biopharma has divested its 70 percent interest in Talicia to Apotex in a deal valued at up to USD 53 million, including potential sales milestones.

Market | 01/09/2026 | By News Bureau |  100

BeOne Medicines Reports Positive Overall Survival Results for Ziihera-Based Regimens in HER2 Plus Gastroesophageal Cancer

BeOne Medicines reports positive Phase 3 results showing improved overall survival with Ziihera-based regimens in patients with HER2-positive gastroesophageal adenocarcinoma.

Market | 01/09/2026 | By News Bureau

Teva Plans Acquisition of Novel Neuroscience Product

Teva plans to acquire BXCL501, a novel dexmedetomidine sublingual film under the US Food and Drug Administration (FDA) review for potential at-home treatment of acute agitation in adults with schizophrenia or bipolar disorder.

Market | 01/09/2026 | By News Bureau

Aurobindo Pharma's Lannett Launches Generic Advair Diskus in US

Aurobindo Pharma’s Lannett launches generic Advair Diskus in the US in 100/50 mcg and 250/50 mcg strengths for asthma and COPD treatment.

Market | 31/08/2026 | By News Bureau